A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity

ABSTRACT Vaccine-induced protection of chimpanzees against laboratory-adapted and syncytium-inducing, multiply passaged primary human immunodeficiency virus type 1 (HIV-1) isolates, but not against non-syncytium-inducing, minimally passaged ones, has been demonstrated. Following challenge with such an isolate, HIV-15016, we obtained complete protection in one of three chimpanzees previously protected against low- and high-dose HIV-1SF2 exposures after immunization with an adenovirus-HIV-1MN gp160 priming–HIV-1SF2gp120 boosting regimen. At challenge, the protected chimpanzee exhibited broad humoral immunity, including neutralizing antibody activity. These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible.

Download Full-text

Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers.

Journal of Clinical Microbiology ◽

10.1128/jcm.28.9.2030-2034.1990 ◽

1990 ◽

Vol 28 (9) ◽

pp. 2030-2034 ◽

Cited By ~ 22

Author(s):

C V Hanson ◽

L Crawford-Miksza ◽

H W Sheppard

Keyword(s):

Human Immunodeficiency Virus ◽

Neutralizing Antibody ◽

Immunodeficiency Virus ◽

Antibody Titers

Download Full-text

Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions

Journal of Virology ◽

10.1128/jvi.79.14.9026-9037.2005 ◽

2005 ◽

Vol 79 (14) ◽

pp. 9026-9037 ◽

Cited By ~ 34

Author(s):

Beda Joos ◽

Alexandra Trkola ◽

Marek Fischer ◽

Herbert Kuster ◽

Peter Rusert ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Viral Replication ◽

Neutralizing Antibody ◽

Replication Capacity ◽

Viral Diversity ◽

Antibody Activity ◽

Plasma Viremia ◽

Treatment Interruptions ◽

Immunodeficiency Virus ◽

Viral Replication Capacity

ABSTRACT Genetic diversity of viral isolates in human immunodeficiency virus (HIV)-infected individuals varies substantially. However, it remains unclear whether HIV-related disease progresses more rapidly in patients harboring virus swarms with low or high diversity and, in the same context, whether high or low diversity is required to induce potent humoral and cellular immune responses. To explore whether viral diversity predicts virologic control, we studied HIV-infected patients who received antiretroviral therapy (ART) for years before undergoing structured treatment interruptions (STI). Viral diversity before initiation of ART and the ability of the patients to contain viremia after STI and final cessation of treatment was evaluated. Seven out of 21 patients contained plasma viremia at low levels after the final treatment cessation. Clonal sequences encompassing the envelope C2V3C3 domain derived from plasma prior to treatment, exhibited significantly lower diversity in these patients compared to those derived from patients with poor control of viremia. Viral diversity pre-ART correlated with the viral replication capacity of rebounding virus isolates during STI. Neutralizing antibody activity against autologous virus was significantly higher in patients who controlled viremia and was associated with lower pretreatment diversity. No such association was found with binding antibodies directed to gp120. In summary, lower pretreatment viral diversity was associated with spontaneous control of viremia, reduced viral replication capacity and higher neutralizing antibody titers, suggesting a link between viral diversity, replication capacity, and neutralizing antibody activity.

Download Full-text